Gilead pushes on with NASH partnership with Novo Nordisk
Genfit, Gilead, Intercept, NASH, Novo Nordisk, semaglutide
0 Comment
Intercept
Novartis takes option on NASH drug from Conatus
Conatus, Gilead, Intercept, Novartis, Shire
0 Comment
Swiss pharma takes option on FXR agonist emricasan.
Genfit encounters trial recruitment problem in hunt for NASH patients
Bristol-Myers Squibb, Genfit, Intercept, NASH
0 Comment
Genfit was among a group of NASH companies publishing updates at the International Liver Congress.
Intercept’s liver drug gets green light from NICE
Allergan, cost-effectiveness, Gilead, Intercept, NICE, primary biliary cholangitis, Shire
0 Comment
NHS patients to get access to drug in PBC.
Intercept’s Ocaliva approved in EU for liver disease
Gilead, Intercept, liver, Ocaliva, orphan, Shire
0 Comment
Potential liver blockbuster gets EU licence.
Gilead to take selonsertib into phase 3 in NASH
Allergan, diabetic kidney disease, Gilead, Intercept, NASH, non-alcoholic steatohepatitis, pulmonary arterial hypertension, Shire
0 Comment
But drug flops in two other indications.
EU regulator recommends Intercept’s potential liver blockbuster
Intercept, liver, orphan, primary biliary cholangitis
0 Comment
Sales forecast to reach $2.6 billion in 2020.
1 2